NCT01527864Unknown2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or With Pegylated Endostatin for Advanced Non-small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- Protgen Ltd
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
A phase II, multicenter, randomized, double-blind, placebo-controlled study was carried out. Patients were randomly assigned to the treatment (PC + pegylated endostatin) or the control group (PC+ placebo). The efficacy was evaluated every six weeks.Follow-up continued until disease progression or death.
详细描述
A randomized phase 2 study, involving patients with advanced non-small-cell lung cancer who had not previously received chemotherapy, compared paclitaxel and carboplatin Plus placebo with paclitaxel and carboplatin plus PEGylated endostatin, with PEGylated endostatin at a dose of 10 mg/m2 intravenously every weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed, newly diagnosed stage IIIB or stage IV cancer or recurrent non-small-cell lung cancer for which they had not received chemotherapy, targeted therapy.
- •Prior radiation therapy was allowed provided that the only sites disease were not located in lung.
- •Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST).
- •≥18 years of age.
- •ECOG performance status of 0 or
- •Life expectancy of at least 12 weeks.
- •Adequate hematologic, hepatic, and renal function.
- •Patients are voluntary to participate and sigh the informed contents.
排除标准
- •Major surgery within the prior 4 weeks.
- •Participating any clinical trial within the prior 4 weeks.
- •Patients had clinically apparent CNS disease ( primary brain tumors, tumor related apoplexy, CNS metastases, carcinomatous meningitis.)
- •Another active malignancy, or any history of other malignancy within the past 3 years except for nonmelanoma skin cancer and carcinoma in situ of the cervix.
- •Pregnant or lactating women.
- •Radiation therapy have not been completed 4 weeks before enrollment.
- •Pulmonary embolus, deep venous thrombosis or bleeding diathesis.
- •Uncontrolled intercurrent illness as following: prior or ongoing uncontrolled hypertension;angina pectoris; congestive cardiac failure; myocardial ischemia, infarction, uncompensated coronary artery disease within the past 12 months; Uncontrolled arrhythmia; Uncontrolled diabetes mellitus; Uncontrolled infection.
- •Grade 2 hemoptysis within the past 6 months.
- •Acute or chronic renal disease.
- •Active hepatitis or HIV.
- •ECG: QTC ≥ 480 ms.
- •Patients on therapeutic doses of heparin.
- •Other conditions that are regarded for exclusion by the investigator.
研究组 & 干预措施
pegylated endostatin
Experimental
干预措施: pegylated endostatin and Paclitaxel-Carboplatin (Drug)
Control
Placebo Comparator
干预措施: Placebo and Paclitaxel-Carboplatin (Drug)
结局指标
主要结局
Progression free survival
时间窗: 6 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete RemissionOvarian CancerNCT00739661Genentech, Inc.104
已完成
2 期
Phase II Study of Hemay005 in Patients With Active Ankylosing SpondylitisActive Ankylosing SpondylitisNCT05407246Tianjin Hemay Pharmaceutical Co., Ltd90
已完成
2 期
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisCystic FibrosisNCT03451045Corbus Pharmaceuticals Inc.447
已完成
2 期
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic SteatohepatitisNASH - Nonalcoholic SteatohepatitisNCT05415722Terns, Inc.162
Unknown
2 期
A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19Covid19NCT04780685Stemedica Cell Technologies, Inc.40